A Study of Ponsegromab in People With Heart Failure

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE

Intervention/treatment:
PONSEGROMAB (PF-06946860)
Medical condition:
HEART FAILURE
Protocol code:
C3651011
Control number:
264697
Status:
Closed
Approved:
September 16, 2022
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT05492500
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer Inc.
Phone:
1-800-718-1021
Sponsor
PFIZER CANADA ULC

Locations

British Columbia

Fraser Clinical Trials Inc
New Westminster, British Columbia, V3L 3W4

Nova Scotia

QEII Health Sciences Centre - Victoria General Site
Halifax, Nova Scotia, B3H 3A7

Ontario

Community Care Building
Winchester, Ontario, K0C 2K0
Corcare
Toronto, Ontario, M1B 5N1
Kawartha Cardiology Clinical Trials
Peterborough, Ontario, K9J 0B2
North York Diagnostic and Cardiac Centre
North York, Ontario, M6B 3H7
Private Practice - Dr. James Cha
Oshawa, Ontario, L1J 2K1
Saul Vizel Professional Medicine Corporation dba Vizel Cardiac Research
Cambridge, Ontario, N1R 7R1
Unity Health Toronto, St. Michael's Hospital
Toronto, Ontario, M5B 1W8
University Hospital - London Health Sciences Centre
London, Ontario, N6A 5A5
Winchester District Memorial Hospital
Winchester, Ontario, K0C 2K0

Quebec

CardioVasc HR Inc
Saint-Jean-sur-Richelieu, Quebec, J3A 1J2
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, H2X 3E4
Centre intégré de santé et de services sociaux de Lanaudière - Hopital Pierre-Le Gardeur.
Terrebonne, Quebec, J6V 2H2
Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski
Rimouski, Quebec, G5L 5T1
Diex Recherche Trois-Rivieres
Trois-Rivières, Quebec, G9A 4P3
Institut de Cardiologie de Montreal
Montreal, Quebec, H1T 1C8

Results

See the results from the trial NCT05492500. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?